Moderna's full pipeline may fuel long-term growth.

U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its ...

Continue » Moderna's shares could soar as it advances its mRNA platform. Compared to older vaccines, those of the mRNA ...

Moderna (MRNA) ended the recent trading session at $49.56, demonstrating a -7.49% change from the preceding day's closing ...

CHONGQING, CHINA - APRIL 26: In this photo illustration, the logo of Moderna, Inc. is displayed on a smartphone screen, with the company's branding visible in the background, on April 26, 2025, in ...

They aren't just "pandemic stocks." ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...

Dwight Morrow was thrilled to land a job at Moderna in June 2023 after its blockbuster Covid-19 vaccine had turned the once-obscure Cambridge biotech into a household name. Morrow, a molecular and ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is a ...

Moderna on Friday posted fourth-quarter revenue that beat estimates, but lost more than expected for the period, as the biotech company continues to slash costs and demand for its Covid vaccine falls.